Innervace’s innovative technology has the potential to be a disease modifying technology by directly replacing neuroanatomy lost to the progression of disease.
This strategy is in stark contrast to currently approved therapies that only temporarily manage symptoms.
The company is based upon technology developed at the University of Pennsylvania.